Breaking Finance News

Shire PLC (LON:SHP) has been retained to Buy in a report by Shore Capital earlier today.

Shore Capital has retained Shire PLC (LON:SHP) to Buy in a statement released on 6/21/2017.

On Monday June 19, 2017, JP Morgan Cazenove released a statement on Shire PLC (LON:SHP) maintained the target price at 6,000.00GBX that suggested an upside of 0.38%.

Having a price of 4,435.50GBX, Shire PLC (LON:SHP) traded -0.91% lower on the day. With the last close up -10.92% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same period. Shire PLC has recorded a 50-day average of 3,937.45GBX and a two hundred day average of 4,399.41GBX. Volume of trade was up over the average, with 3,246,362 shares of SHP changing hands over the typical 2,603,380

Performance Chart


With a total market value of 0 GBX, Shire PLC has price-earnings ratio of 52.60 with a one year low of 3,603.50GBX and a one year high of 5,377.00GBX .

A total of 18 analysts have released a report on Shire PLC. Six analysts rating the company a strong buy, sixteen analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of 73.73GBX.

More About Shire PLC (LON:SHP)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.